We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Predicts Low Birth Weight

By LabMedica International staff writers
Posted on 04 Sep 2012
A protein found in the blood of pregnant women can predict if they are likely to have a fetus that does not grow properly. More...


The assay could lead to a widely available blood test that could help develop ways for improving the outcomes of women and their children who face this high risk of stillbirth and long-term health complications.

Scientists at the Ottawa Hospital Research Institute (ON, Canada) conducted a nested case-control study to examine circulating levels of Insulin Growth Factor Binding Protein 4 (IGBP-4) and other biomarkers by Western blot in early gestation in 36 women who went on to develop fetal growth restriction (FGR) and 36 controls having normal-weight babies.

The investigators found that IGFBP-4 was elevated in early pregnancy compared with nonpregnant women and women in later pregnancy, consistent with the presence of abundant extravillous trophoblasts and decidual cells that highly expressed IGFBP-4. High expression of pregnancy-associated plasma protein-A (PAPP-A) was observed in extravillous trophoblasts and decidual cells in early pregnancy but hardly detectable in the circulation at the same time. The women with high levels of IGFBP-4 were 22 times more likely to give birth to tiny babies, defined as the smallest 5% by weight for their gestational age, than women with normal levels of IGFBP-4.

Andrée Gruslin, MD, the lead author of the study, said, "Usually, we don’t find out until later in a pregnancy that a fetus isn’t growing properly, but this test can tell us in the first trimester if there’s likely to be a problem. By identifying these high-risk pregnancies early on, we will be able to monitor these women more closely and hopefully help them deliver a healthier baby.” Dr. Gruslin hopes that her studies on IGFBP-4 could lead to new approaches that would improve fetal growth in high-risk pregnancies. This condition, called Fetal Growth Restriction or Intrauterine Growth Restriction, is thought to affect 3%-5% of all pregnancies, and cause close to half of all stillbirths. The study was published on August 1, 2012, in the Journal of Clinical Endocrinology and Metabolism.

Related Links:
Ottawa Hospital Research Institute



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.